



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

P&T Date: 12/04/2025

Pembrolizumab Products

Keytruda® (pembrolizumab)

Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph)

HCPCS: Keytruda: J9271; Keytruda Qlex: J9277

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Treatment must follow the FDA approved indications or National Comprehensive Cancer Network (NCCN) guidelines when it is a Category 1 or 2A recommendation
 - i. Must be used with concomitant treatment according to FDA indication or NCCN Category 1 or 2A recommendation
 - b. Prescribed by or in consultation with an oncologist or hematologist
 - c. No prior failure of a programmed death receptor-1 (PD-1 or PD-L1) inhibitor
 - d. Patient is not receiving therapy for a chronic condition, such as an autoimmune disease, that requires treatment with a systemic immunosuppressant
 - e. Trial and failure, intolerance, or a contraindication to the preferred products as listed in the BCBSM/BCN utilization management medical drug list
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: Align with FDA recommended dosing
 - b. Authorization Period: Aligns with FDA recommended or guideline supported treatment duration and provided for at least 60 days and up to 6 months at a time
 - c. Renewal Criteria:
 - i. Treatment continued until unacceptable toxicity or disease progression occurs
 - ii. Renewal beyond 24 months of total therapy will be considered according to FDA approved drug labelling
 - iii. Metastatic non-small cell lung cancer: Treatment until unacceptable toxicity or disease progression for up to a total of 24 months of therapy

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Keytruda and Keytruda Qlex are programmed death receptor-1 (PD-1)-blocking antibody indicated for the following:
 - For the treatment of patients with unresectable or metastatic melanoma
 - For the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection
 - In combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations
 - In combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC
 - As a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) $\geq 1\%$] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
 - Stage III where patients are not candidates for surgical resection or definitive chemoradiation or
 - Metastatic
 - As a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda
 - For the treatment of patients with resectable (tumors ≥ 4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
 - As a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥ 4 cm), II, or IIIA NSCLC
 - In combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic pleural mesothelioma (MPM)
 - For the treatment of adult patients with resectable locally advanced head and neck squamous cell cancer (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent (Keytruda only)

- In combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC
- As a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test
- As a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy
- For the treatment of adult patients with relapsed or refractory classic Hodgkin lymphoma (cHL) (Keytruda only)
- For the treatment of pediatric patients with refractory cHL or cHL that has relapsed after 2 or more lines of therapy (Keytruda only)
- For the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or who have relapsed after 2 or more prior lines of therapy (Keytruda only)
- In combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer
- For the treatment of patients with locally advanced or metastatic urothelial carcinoma who
 - Are not eligible for any platinum-containing chemotherapy OR
 - Have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- For the treatment of patients with Bacillus Calmette-Guerin (BCG) unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
- For the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
- For the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test
- For the treatment of locally advanced, unresectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, as first-line treatment
- In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma

- For the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
 - In combination with platinum- and fluoropyrimidine-based chemotherapy OR
 - As a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test
- In combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA)
- In combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test
- As a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test
- For the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen
- In combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC)
- For the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC)
- In combination with axitinib, for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
- In combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC
- For the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
- In combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma
- In combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation
- As a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation

- For the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options
- For the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation
- For the treatment of patients with high-risk early-stage triple negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery
- In combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA approved test
- The National Comprehensive Cancer Network (NCCN) guidelines category 1 and 2A recommendations are based on uniform NCCN consensus that the recommendations are appropriate. Treatment regimens have been studied and shown to be efficacious when administered as listed in the guidelines. Category 2B and 3 recommendations do not have a high level of evidence to support use and also do not have a uniform consensus from the NCCN panel that the recommendations are appropriate.
- There are no studies to support use of Keytruda following failure. NCCN treatment guidelines also do not recommend use of Keytruda or other PD-L1 checkpoint inhibitors following a previous failure.
- Keytruda has not been studied in patients on chronic immunosuppressant therapy and therefore, should not be used in patients on chronic immunosuppressants.

References:

1. Keytruda [prescribing information]. Whitehouse Station, NJ: Merck and Company, Inc.; August 2025.
2. Keytruda Qlex [prescribing information]. Rahway, NJ: Merck Sharp and Dohme LLC; September 2025.
3. National Comprehensive Cancer Network. Uterine neoplasms (Version 3.2025). 2025 March 7. Available at: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed on September 29, 2025.
4. National Comprehensive Cancer Network. Breast cancer (Version 4.2025). 2025 April 17. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed on September 19, 2025.
5. National Comprehensive Cancer Network. Cutaneous melanoma (Version 2.2025). 2025 Jan 28. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed on September 23, 2025.
6. National Comprehensive Cancer Network. Non-small cell lung cancer (Version 8.2025). 2025 August 15. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on September 23, 2025.
7. National Comprehensive Cancer Network. Mesothelioma: pleural (Version 1.2026). 2025 Sept 19. Available at: https://www.nccn.org/professionals/physician_gls/pdf/meso_pleural.pdf. Accessed on September 24, 2025.
8. National Comprehensive Cancer Network. Head and neck cancers (Version 5.2025). 2025 August 12. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed on September 24, 2025.
9. National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2025). 2025 Jan 20. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed on September 25, 2025.
10. National Comprehensive Cancer Network. B-cell lymphomas (Version 3.2025). 2023 Aug 18. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed on September 29, 2025.
11. National Comprehensive Cancer Network. Bladder cancer (Version 1.2025). 2025 March 25. Available at: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 24, 2025.
12. National Comprehensive Cancer Network. Colon cancer (Version 4.2025). 2025 June 27. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed on September 25, 2025.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

13. National Comprehensive Cancer Network. Gastric cancer (Version 3.2025). 2025 August 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed on September 25, 2025.
14. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers (Version 4.2025). 2025 August 22. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed on September 25, 2025.
15. National Comprehensive Cancer Network. Cervical cancer (Version 4.2025). 2025 March 24. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed on September 25, 2025.
16. National Comprehensive Cancer Network. Hepatocellular carcinoma (Version 1.2025). 2025 March 20. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed on September 29, 2025.
17. National Comprehensive Cancer Network. Biliary tract cancers (Version 2.2025). 2025 July 2. Available at: https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. Accessed on September 29, 2025.
18. National Comprehensive Cancer Network. Merkel cell carcinoma (Version 1.2026). 2025 Sept 2. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. Accessed on September 29, 2025.
19. National Comprehensive Cancer Network. Squamous cell skin cancer (Version 1.2026). 2025 Sept 2. Available at: https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed on September 29, 2025.
20. National Comprehensive Cancer Network. Kidney cancer (Version 1.2026). 2025 July 24. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed on September 29, 2025.
21. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet*. 2014 Sep 20 ;384 (9948): 1109 - 17.
22. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. *NEJM*. 2015; 372: 2018 – 28.
23. Robert C. Pembrolizumab versus ipilimumab in advanced melanoma. *NEJM*. 2015; 372: 2521 - 32.
24. Kurzawski G, Suchy J, Debniak T, et al. Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool. *Ann Oncol*. 2004; 15 (Suppl 4): iv283 - 4.
25. Savage KJ. Primary mediastinal large b-cell lymphoma. *The Oncologist*. 2006; 11: 488 - 95.

Policy History		
#	Date	Change Description
3.1	Effective Date: 05/13/2026	UM medical management system update for BCBS, BCN, MAPPO, and BCNA Keytruda Qlex
3.0	Effective Date: 12/04/2025	Updated to include Keytruda Qlex. Name of the policy was changed from Keytruda to the Pembrolizumab Products Policy.
2.9	Effective Date: 05/27/2025 P&T Date: 04/10/2025	Updated to include the trial and failure of preferred products statement
2.8	Effective Date: 02/13/2025	Annual review of criteria was performed, no changes were made
2.7	Effective Date: 02/08/2024	Annual review of criteria was performed, no changes were made
2.6	Effective Date: 02/02/2023	Updated approval length to allow for FDA recommended dosing for at least 60 days and up to 6 months at a time
2.5	Effective Date: 02/10/2022	Annual review of criteria was performed, no changes were made
2.4	Effective Date: 02/04/2021	Updated authorization periods to mirror the recommended treatment duration in the package insert
2.3	Effective Date: 12/01/2020	UM medical management system update for BCBS for Keytruda
2.2	Effective Date: 02/06/2020	Annual Review
2.1	Effective Date: 02/14/2019	New indication for hepatocellular carcinoma, update criteria to match FDA indication and NCCN recommendations.
2.0	Effective Date: 11/01/2018	Update criteria with new indications for: Metastatic nonsquamous NSCLC Locally advanced or metastatic urothelial carcinoma for: • Patients ineligible for cisplatin with PD-L1 ≥ 10 • Patients ineligible for platinum-based chemotherapy Recurrent or metastatic cervical cancer Refractory primary mediastinal large B-cell lymphoma (PMBCL)
1.9	Effective Date: 05/03/2018	Update criteria with new indication for Gastric Cancer
1.8	Effective Date: 02/12/2018	UM medical management system update for MAPPO and BCNA for Keytruda
1.7	Effective Date: 11/09/2017	Update criteria with new indication for Urothelial carcinoma and Microsatellite Instability-High Cancers
1.6	Effective Date: 08/10/2017	Update criteria with new indication for refractory or relapsed classical Hodgkin's Lymphoma
1.5	Effective Date: 05/04/2017	Update criteria with new indication for first line treatment in metastatic NSCLC
1.4	Effective Date: 02/09/2017	Update criteria with new indication for head and neck squamous cell carcinoma
1.3	Effective Date: 05/05/2016	Update criteria: First line therapy for metastatic melanoma

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

1.2	Effective Date: 02/11/2016	New Indication: NSCLC
1.1	Effective Date: 04/01/2015	UM medical management system update for HMO for Keytruda
1.0	Effective Date: 02/12/2015	New Drug Review

** The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.*